Obeticholic Acid Approved for the Treatment of Chronic Liver Disease

Primary biliary cholangitis is a chronic liver disease where the bile ducts in the liver become inflamed causing accumulation of bile, leading to cirrhosis.

The U.S Food and Drug Administration (FDA) has granted approval for Ocaliva (obeticholic acid) for the treatment of primary biliary cholangitis (PBC).

Primary biliary cholangitis is a rare chronic liver disease where the bile ducts in the liver become inflamed causing accumulation of bile, leading to scarring of liver or cirrhosis.

New Treatment Provides Hope for Liver Disease Sufferers
Norursodeoxycholic acid provided a safe and effective option for patients with primary sclerosing cholangitis and the treatment warrants further investigation.

‘The U.S. Food and Drug Administration granted accelerated approval for Ocaliva (obeticholic acid) for the treatment of primary biliary cholangitis (PBC).’

The only approved treatment for PBC was ursodeoxycholic acid (UDCA) and patients who respond inadequately to this treatment can use Ocaliva in combination with UDCA.

Ocaliva interacts with farnesoid X receptor (FXR), which plays a key role in bile acid regulation. By binding to this receptor Oclavia suppresses bile accumulation and increases the flow, leading to a reduction in bile levels in the liver.

The drug was tested in 216 participants, wherein after one-year of follow-up, reductions in bile levels was higher among Ocaliva-treated participants compared to placebo-treated participants.

Digestive Hormone 'Secretin' Has an Important Role In Chronic Liver Diseases
High levels of a digestive hormone called secretin may play an important role in the management of certain chronic liver diseases.

Some of the side effects of Ocaliva include fatigue, abdominal pain, throat pain, dizziness and itching of the skin. Ocaliva is manufactured by New York-based Intercept Pharmaceuticals.

Source-Medindia

Alcohol Ups Liver Damage in People With Hepatitis C
Alcohol promotes faster development of fibrosis and progression to cirrhosis in people with hepatitis C, making drinking a dangerous and often deadly activity.

Treating Hepatitis C at Earlier Stage is Cheaper and Could Save Lives
Treating hepatitis C patients could save $800 billion in the next 20 years and free up treatment for thousands of people with other liver diseases.